DDX21 and neoplasm: High expression of DDX21, a known nuclear autoantigen2,19,20, in MSI tumors may induce DDX21-specific autoimmunity against tumor cells that contributes to better clinical outcomes in cancer patients and perhaps better response to immune checkpoint inhibitor therapy.